Published • loading... • Updated
Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment - South Shore & Nova Scotia News
Summary by southshorenow.ca
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment - South Shore & Nova Scotia News
Retatrutide (LY3437943) is a first-in-class triple agonist medication that simultaneously activates three hormone receptors to treat obesity and type 2 diabetes, showing weight loss results of up to 24% in clinical trials. Unlike earlier treatments that target one or two pathways, this experimental drug works on GIP, GLP-1, and glucagon receptors at once, making it potentially more effective than current options including the GLP-3 RT peptide an…
·Shelburne, Canada
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
